You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

By Therapeutic Class

Protein therapeutics

Protein therapeutics development and manufacturing is a highly complex process.  In both process development as well as commercial manufacturing, the protein therapeutics workflow includes cell optimization, cell culture, harvest, purification, formulation and fill and finish.

This class includes the bioprocessing of 

  • Monoclonal Antibodies
  • Antibody fragments
  • Fc and Albumin fusions
  • Blood factors
  • Protein-based vaccines

Protein therapeutics

Gene Therapy

Gene and gene-modified cell therapies treat diseases by delivering therapeutic DNA into a patient’s cells. To ensure effective clinical translation and commercialization, the bioprocessing community must devote intense effort to scalability of vector manufacturing.

This class includes the bioprocessing of

  • Plasmid DNA
  • Viral Vectors (as Gene Therapy or raw material for Cell Therapy)

Gene therapy

Vaccines

Vaccine production using mammalian or insect cell cultures are emerging to overcome the limitations of traditional egg-based vaccines production systems. These new systems require novel, faster and more flexible manufacturing solutions and processes.

This class includes the bioprocessing of

  • Whole particle virus (animal and human)
  • Virus-like Particles

Vaccines

macro molecules

Increasingly used as drug delivery vehicles, this class inludes the bioprocessing of

  • Whole Particle Virus (Human and Animal)
  • Virus Like Particles  (VLPs) 
  • Plasmid DNA
  • Exosomes

Macro molecules

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drug composed of an antibody linked to a biologically active drug compound. These novel, targeted agents combine the unique, high specificity, properties and anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but not sufficiently cytotoxic, with the potent cell killing activity of cytotoxic small molecule drugs that are too toxic to be used on their own.

Antibody drug conjugates